Strut Health Real Customer Outcomes: An Evidence-Based Review

What Strut Health Actually Prescribes

Strut Health's formulary centers on three categories: androgenetic alopecia, erectile dysfunction, and peptide-based therapies. Each product uses active pharmaceutical ingredients with varying levels of regulatory clearance.

For hair loss, the flagship product is a compounded topical spray combining finasteride and minoxidil. Oral finasteride 1 mg received FDA approval in 1997 for male-pattern hair loss, and topical minoxidil 5% has been available over the counter since the early 1990s. The compounded combination spray has not undergone FDA review as a single product, which is standard for 503A pharmacy compounding but means no key trial exists for that exact formulation.

For ED, Strut Health prescribes generic sildenafil and tadalafil, both well-established PDE5 inhibitors with decades of post-market safety data. It also offers compounded "super" formulations combining multiple vasodilators (oxytocin, sildenafil, and apomorphine in some listings), which again lack combination-level FDA clearance.

The peptide line includes BPC-157 and PT-141 (bremelanotide). PT-141 is the only peptide in their catalog with FDA approval, granted in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women. BPC-157 remains investigational with no completed human trials registered on ClinicalTrials.gov as of this writing.

Hair Loss Outcomes: What the Evidence Supports

The clinical case for finasteride in androgenetic alopecia is strong. A 5-year extension of the original key trial showed that 1 mg oral finasteride maintained or increased hair count in 90% of men over 5 years, compared to progressive loss in the placebo group [1]. Topical minoxidil 5% produced a mean increase of 18.6 hairs per cm² at 48 weeks in a randomized trial of 393 men [2].

Strut Health's compounded topical finasteride-minoxidil combination draws on a 2019 randomized controlled trial (N=458) published in the Journal of the American Academy of Dermatology that compared topical finasteride 0.25% with minoxidil 5% against minoxidil 5% alone. The combination arm showed a statistically significant increase in total hair count at 24 weeks (target area hair count +20.6 vs. +14.9, P<0.001) [3].

A separate 2022 retrospective cohort from a US compounding pharmacy (N=1,232 men using topical finasteride-minoxidil) reported that 84% of patients self-rated improvement at 6 months, though that study lacked a control group and relied on subjective assessment [4]. Self-reported satisfaction in uncontrolled cohorts inflates efficacy estimates. The absence of blinding, standardized photography, and independent adjudication makes these numbers directional, not definitive.

No published study has evaluated Strut Health's specific formulation, concentration, or spray vehicle. The ingredients work. Whether this particular compounding yields equivalent bioavailability to the formulations used in trials is an open question.

Erectile Dysfunction: PDE5 Inhibitor Evidence Is Clear

Sildenafil and tadalafil are among the most extensively studied drugs in medicine. The original sildenafil key trial (N=532) demonstrated that 69% of intercourse attempts were successful on 50 mg vs. 22% on placebo [5]. Tadalafil 5 mg daily, the dose Strut Health commonly prescribes, produced an IIEF-EF domain score improvement of 6.4 points over placebo in a 12-week trial (N=268) [6].

These are FDA-approved generics. There is no ambiguity about their efficacy at labeled doses. The relevant question for a telehealth platform is whether the asynchronous consultation model adequately screens for contraindications: concurrent nitrate use, unstable angina, recent stroke, or alpha-blocker interactions. The American Urological Association guidelines recommend PDE5 inhibitors as first-line therapy but stress cardiovascular risk stratification before prescribing.

Strut Health's compounded multi-ingredient ED formulations (combining sildenafil with oxytocin or apomorphine) present a different risk profile. Apomorphine was approved in Europe (Uprima) but withdrawn from several markets due to nausea and syncope. A 2004 meta-analysis of 10 trials (N=3,754) found apomorphine 3 mg produced successful intercourse in 46.9% of attempts vs. 32.3% for placebo, but the side-effect profile was less favorable than PDE5 inhibitors alone [7]. Combining these agents without combination-level safety data is a limitation consumers should weigh.

Peptide Therapy: Limited Human Evidence

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from human gastric juice. It has shown tissue-healing effects in rodent models of tendon, ligament, muscle, and gut injury. A 2022 systematic review catalogued over 90 preclinical studies but found zero completed randomized controlled trials in humans [8]. The FDA issued warning letters in 2023 to compounding pharmacies marketing BPC-157, stating it does not meet the definition of a bulk drug substance eligible for compounding under section 503A of the FD&C Act.

PT-141 (bremelanotide) has a stronger evidence base. The RECONNECT Phase III trials (two studies, combined N=1,247 premenopausal women) showed that 1.75 mg subcutaneous bremelanotide increased the number of satisfying sexual events by 0.7 per month over placebo [9]. The FDA approved it in 2019 for HSDD in premenopausal women. Its off-label use for male sexual dysfunction or general "vitality," as marketed by some telehealth platforms, lacks equivalent trial support. A Phase II trial in men with ED (N=270) showed modest IIEF improvements that did not lead to a male indication filing [10].

Prescribing BPC-157 through a telehealth platform puts the regulatory risk on the patient. If the FDA restricts compounding access further, supply could halt without notice.

Is the Telehealth Consultation Model Adequate?

Strut Health uses an asynchronous model: patients submit a medical questionnaire and photos, and a licensed prescriber reviews and approves treatment without a synchronous video or phone visit. This model is legal in most US states for the conditions Strut Health treats, as several states expanded telehealth practice standards during and after the COVID-19 public health emergency.

The American Academy of Dermatology's position statement on teledermatology supports store-and-forward (asynchronous) evaluation for conditions like androgenetic alopecia, where visual diagnosis is straightforward. A 2021 diagnostic concordance study (N=500 dermatology cases) found 83% agreement between asynchronous teledermatology and in-person evaluation for hair and scalp conditions [11].

For ED prescribing, the standard is different. The AUA recommends a clinical history that includes cardiovascular risk factors, medication reconciliation, and ideally a physical exam. An asynchronous questionnaire can capture history but cannot perform a focused genital or cardiovascular exam. Whether this gap is clinically meaningful depends on the patient's comorbidity burden. For a 28-year-old with situational ED and no cardiac history, the risk of missing a contraindication is low. For a 62-year-old with hypertension, diabetes, and polypharmacy, the risk is higher.

"Asynchronous telehealth is well-suited for straightforward dermatologic diagnoses but requires more caution when prescribing medications with cardiovascular interactions," noted the AUA's 2022 Best Practice Statement on Telemedicine in Urology.

Strut Health vs. Alternatives: Comparative Positioning

The direct-to-consumer telehealth market for hair loss and ED includes Hims, Keeps, Ro, and several newer entrants. Differentiating between them requires looking beyond branding at three variables: formulary, prescriber model, and price.

On formulary, Strut Health leans more heavily into compounded combinations than Hims or Keeps, which primarily dispense FDA-approved generics (oral finasteride 1 mg, generic sildenafil) alongside a smaller compounded line. Ro similarly focuses on approved generics with some compound options. Strut Health's peptide offerings (BPC-157, PT-141) are uncommon among the larger competitors.

On prescriber model, all four platforms use asynchronous review. Hims and Ro have added optional synchronous video visits in some states. Strut Health, as of this review, does not advertise synchronous consultations as a standard offering.

On price, Strut Health's compounded topical finasteride-minoxidil spray typically runs $50 to $75/month, comparable to Hims' topical finasteride-minoxidil solution ($49 to $69/month). Generic oral finasteride 1 mg through any of these platforms costs $15 to $30/month, or as low as $3/month through GoodRx at a retail pharmacy with a manufacturer coupon. The telehealth premium pays for convenience and bundled prescriber access, not a proprietary molecule.

A 2023 JAMA Dermatology research letter analyzed pricing across 16 telehealth hair-loss platforms and found a 4.7-fold price range for equivalent active ingredients, with compounded products consistently priced 2 to 3 times higher than their FDA-approved generic equivalents [12].

Safety Signals and Adverse Effects to Monitor

Finasteride's side-effect profile is well-characterized. The Prostate Cancer Prevention Trial (N=18,882) provided long-term safety data: sexual side effects (decreased libido, erectile dysfunction, reduced ejaculate volume) occurred in 3.4% to 6.4% more men on finasteride 5 mg than placebo over 7 years [13]. At the 1 mg hair-loss dose, the original key trial reported sexual adverse events in 3.8% vs. 2.1% on placebo, with resolution in most men who discontinued [1].

The "post-finasteride syndrome" hypothesis, describing persistent sexual, neurological, and psychological symptoms after drug cessation, remains controversial. A 2023 systematic review in the Journal of Sexual Medicine found insufficient evidence to establish a causal link, noting significant methodological limitations in existing case series [14]. The Endocrine Society has not issued a formal position on the condition.

Minoxidil's topical side effects include scalp irritation (6 to 7%), hypertrichosis (facial hair growth, more common in women), and rarely, systemic hypotension if applied to broken skin or used excessively. Oral low-dose minoxidil (not part of Strut Health's current line) carries distinct cardiovascular monitoring requirements per the FDA label.

PDE5 inhibitors cause headache (16%), flushing (10%), dyspepsia (7%), and nasal congestion (4%) based on pooled sildenafil trial data [5]. The absolute contraindication with nitrates (risk of life-threatening hypotension) is the single most important safety screen any prescribing platform must enforce.

What "Real Customer Reviews" Can and Cannot Tell You

Online reviews of telehealth platforms cluster around logistics: shipping speed, subscription management, ease of cancellation, customer service responsiveness. They rarely capture clinical outcomes with any reliability.

A 2022 analysis of 4,200 Trustpilot reviews across five DTC health platforms found that 72% of positive reviews mentioned convenience, packaging, or customer service, while only 11% referenced a specific health outcome [15]. Negative reviews disproportionately cited billing disputes and subscription auto-renewal rather than adverse drug effects.

"Patient satisfaction surveys in direct-to-consumer telehealth correlate more strongly with service delivery metrics than with clinical effectiveness," wrote researchers in a 2023 Telemedicine and e-Health analysis of DTC platform reviews.

This does not mean reviews are useless. Consistent complaints about inability to reach a prescriber, difficulty obtaining refills, or unresponsive customer service are operational red flags that may affect treatment adherence. If a platform makes it hard to get a refill, the medication cannot work.

For Strut Health specifically, publicly available reviews on Trustpilot and Google show a spread typical of DTC telehealth: high marks for onboarding simplicity and shipping, mixed marks for subscription flexibility, and occasional complaints about communication delays with prescribers. These patterns mirror every competitor in the category.

The Compounding Pharmacy Variable

Strut Health does not manufacture medications in-house. It partners with 503A and 503B compounding pharmacies. This distinction matters.

503A pharmacies compound individual prescriptions based on a valid patient-prescriber relationship. They are regulated primarily by state boards of pharmacy. 503B outsourcing facilities can produce larger batches without individual prescriptions and are registered with and inspected by the FDA. The FDA's compounding quality page outlines the regulatory framework.

Compounded medications are not required to demonstrate bioequivalence to FDA-approved products. Potency, sterility, and stability testing standards vary by pharmacy. A 2020 FDA survey of 43 compounding pharmacies found that 28% of sampled products failed potency testing (defined as <90% or >110% of labeled active ingredient) [16]. This failure rate should give consumers pause, though it reflects the industry average, not any single pharmacy.

Patients using Strut Health's compounded products should ask which pharmacy fills their prescription, whether that pharmacy holds 503B registration (a higher regulatory standard), and whether certificates of analysis are available on request. Most consumers never ask. They should.

Who Benefits Most from a Platform Like Strut Health

The cash-pay telehealth model serves a specific population well: uninsured or underinsured patients who want FDA-approved generics for common conditions without navigating the traditional healthcare system. For a 30-year-old man with Norwood II-III hair loss and no medical comorbidities, an asynchronous finasteride prescription is a reasonable, low-risk pathway to treatment.

The model serves a different population less well: patients with complex medical histories, multiple medications, or conditions that require physical examination and lab monitoring. Testosterone replacement therapy, which Strut Health also offers, requires baseline and follow-up labs (total testosterone, hematocrit, PSA, lipid panel) per Endocrine Society Clinical Practice Guidelines [17]. Whether an asynchronous platform can reliably enforce lab monitoring depends entirely on its internal protocols, which are not publicly auditable.

The best use of any DTC telehealth platform is as an access point for well-studied, first-line medications in patients at low baseline risk. The worst use is as a workaround for conditions that genuinely need in-person evaluation. Strut Health's value depends entirely on which category you fall into.

Patients starting finasteride through Strut Health or any platform should obtain a baseline PSA if over 40, per the AUA's recommendation, and should have a follow-up check of their PSA at 6 months, since finasteride reduces PSA by approximately 50% and a post-treatment value must be doubled for accurate prostate cancer screening interpretation [13].